StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) company profile

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

About COSCIENS Biopharma

Perfumes, Cosmetics & Other Toilet Preparations, SIC 2844

COSCIENS Biopharma Inc. is a biopharmaceutical enterprise focused on the extraction, production, and commercialization of active ingredients from natural sources. Its operations encompass biopharmaceutical development as well as active ingredients for the nutraceuticals market, notably oat-based pipeline products such as oat-beta glucan and avenanthramides, along with yeast-derived beta glucan. The organization also advances and scales proprietary Pressurized Gas eXpanded technology. Its customer base includes commercial distributors, healthcare partners, and biopharmaceutical clients across global regions.

The company engages in business across international territories, recording commercial and partner activities in countries such as the United States, Germany, the United Kingdom, and Colombia. Executive offices and corporate headquarters are located in Toronto, Ontario, Canada.

Summary of the business section of COSCIENS Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
COSCIENS Biopharma Inc.
Headquarters
Toronto, A6
Address
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53 M5K 1E7
Phone
(843) 900-3201
Employees
28, Dec 31, 2025
Industry
Perfumes, Cosmetics & Other Toilet Preparations
Incorporated in
A6
Fiscal year ends
December 31
Auditor
Deloitte LLP, Montreal, Canada

Stock & identifiers

Ticker
CSCIF
Former tickers
AEZS until Apr 9, 2025
Exchange
OTC
IPO date
May 10, 2000
Shares outstanding
3M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-4 reverse, May 3, 2024; 1-for-25 reverse, Jul 21, 2022; 1-for-100 reverse, Nov 20, 2015; 1-for-6 reverse, Oct 5, 2012
SEC CIK
1113423
CUSIP
22112H101
ISIN
CA22112H1010
FIGI
BBG000LZRK22
Share class FIGI
BBG001S63T33
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

COSCIENS Biopharma's leadership is listed in its proxy statement (Form DEF 14A).

Employees

Headcount reported in annual reports

“at December 31, 2025, we had a total of 28 active employees, of which 23 were based in Canada, 4 were based in Frankfurt, Germany and”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 6, 2026DeregistrationTermination of SEC registration (Form 15)
Aug 26, 2025DelistingNotice of delisting from exchange (Form 25)
Aug 7, 2024Name changeName changed from Aeterna Zentaris Inc. to COSCIENS Biopharma Inc.
Apr 14, 2017ListingRegistration of securities on an exchange (Form 8-A)
May 25, 2004Name changeName changed from AETERNA LABORATORIES INC to Aeterna Zentaris Inc.

See a number that looks wrong?